-
Merck &Co. drops osteoporosis drug odanacatib.
Nature reviews. Drug discovery 20160929
-
The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women.
Drug metabolism and disposition: the biological fate of chemicals 20160901
-
Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans.
Drug metabolism and disposition: the biological fate of chemicals 20140501
-
Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.
The Journal of clinical endocrinology and metabolism 20140201
-
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
The Journal of clinical endocrinology and metabolism 20130201
-
Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20121101
-
Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.
Journal of medicinal chemistry 20121025
-
Potential first-in-class osteoporosis drug speeds through trials.
Nature medicine 20120801
-
(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.
Journal of medicinal chemistry 20120726
-
Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey.
Bone 20120601
-
Bone metastases: molecular mechanisms and novel therapeutic interventions.
Medicinal research reviews 20120501
-
Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.
Expert opinion on drug discovery 20120401
-
Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120301
-
Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120301
-
Inhibition of cathepsin K for treatment of osteoporosis.
Current osteoporosis reports 20120301
-
Odanacatib: location and timing are everything.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120301
-
Quantitative determination of odanacatib in human plasma using liquid-liquid extraction followed by liquid chromatography-tandem mass spectrometry analysis.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120215
-
Potential role of odanacatib in the treatment of osteoporosis.
Clinical interventions in aging 20120101
-
[Innovations in the treatment of osteoporosis].
Deutsche medizinische Wochenschrift (1946) 20111201
-
The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
Bone 20111001
-
New targets for intervention in the treatment of postmenopausal osteoporosis.
Nature reviews. Rheumatology 20110920
-
Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway.
Drug metabolism and disposition: the biological fate of chemicals 20110601
-
[Cathepsin K inhibitor: new therapy approach against osteoporosis. Pharmacological target in the osteoclast].
MMW Fortschritte der Medizin 20110512
-
Osteoporosis: now and the future.
Lancet (London, England) 20110409
-
Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110201
-
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110201
-
Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
Bioorganic & medicinal chemistry letters 20110201
-
Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110201
-
[Odanacatib (MK-0822)].
Clinical calcium 20110101
-
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Clinical breast cancer 20101201
-
New approaches to treating and preventing bone metastases.
Current opinion in supportive and palliative care 20100901
-
Emerging targets in osteoporosis disease modification.
Journal of medicinal chemistry 20100610
-
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100501
-
The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
Bone 20100501
-
Exploiting new targets for old bones.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100501
-
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
Bioorganic & medicinal chemistry letters 20100201
-
Peptidomimetic inhibitors of cathepsin K.
Current topics in medicinal chemistry 20100101
-
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
IDrugs : the investigational drugs journal 20091201
-
Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools.
Biological chemistry 20090901
-
Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
Clinical pharmacology and therapeutics 20090801
-
[Bone remodeling: new therapeutic approaches].
Revue medicale suisse 20090610
-
[Prevention of joint destruction by osteoclast-targeting therapy in search of new tools, such as OPG or cathepsin K inhibitor].
Clinical calcium 20090301
-
A practical enantioselective synthesis of odanacatib, a potent Cathepsin K inhibitor, via triflate displacement of an alpha-trifluoromethylbenzyl triflate.
The Journal of organic chemistry 20090220
-
Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.
Bioorganic & medicinal chemistry letters 20090201
-
Formulation and stability of itraconazole and odanacatib nanoparticles: governing physical parameters.
Molecular pharmaceutics 20090101
-
Cathepsin K inhibitors as treatment of bone metastasis.
Current opinion in supportive and palliative care 20080901
-
Molecule of the month. Odanacatib.
Drug news & perspectives 20080601
-
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Bioorganic & medicinal chemistry letters 20080201
